HER2 overexpression correlates with survival after curative resection of pancreatic cancer
HER2 overexpression correlates with survival after curative resection of pancreatic cancer
复制标题
DOI：
10.1111/j.1349-7006.2009.01176.x
复制
发表时间：
2009-07-01
期刊：
影响因子：
5.7
通讯作者：
Hirakawa, Kosei
中科院分区：
文献类型：
--
作者：
Komoto, Masahiro;Nakata, Bunzo;Hirakawa, Kosei
HER2的过度表达与几种实体肿瘤的临床结果有关，例如乳腺癌。然而，HER2在胰腺癌中的过度表达与生存的相关性仍不清楚。研究HER2过表达对胰腺导管癌患者生存率的影响。对129例无血行转移或腹膜播散的胰腺癌进行了免疫组织化学染色，并与术后生存资料进行了对比分析。为了确定HER2在这一系列胰腺癌中的过度表达，使用了HercepTest中包含的多克隆抗体，该多克隆抗体被广泛用于乳腺癌中HER2过表达的临床检测。免疫反应性根据HercepTest评分指南中提出的评分标准进行分类。0分22例(17.1%)，1+28例(21.7%)，2+41例(31.8%)，3+38例(29.4%)。因此，HER2过表达(评分2+或3+)79例(61.2%)。HER2高表达患者的生存时间明显短于HER2正常表达患者(评分为0.0078或1+)(中位生存期分别为14.7月和20.7月，经对数等级检验，P=0.05)。在多因素生存分析中，HER2过度表达仍然是一个独立的预后因素(风险比，1.806；P=0.0258)。有相当大比例的胰腺癌HER2过度表达，这种酪氨酸激酶受体的过度表达被证明是预后较差的独立因素。这些结果应该会鼓励进一步研究使用针对HER2蛋白的新的分子靶向药物来提高胰腺癌患者的存活率。(癌症科学2009；100：1243-1247)
HER2 overexpression has been linked to clinical outcomes in several solid tumors, such as breast cancer. However, the correlation between HER2 overexpression and survival in pancreatic carcinoma remains unclear. The impact of HER2 overexpression on survival in pancreatic ductal cancer was examined. Immunohistochemical staining of 129 pancreatic cancers without hematogenous metastases or peritoneal dissemination treated by macroscopically curative resection were analyzed in association with survival data. To determine HER2 overexpression in this pancreatic cancer series, the polyclonal antibody included in HercepTest, which is used worldwide for clinical examination of HER2 overexpression in breast cancer, was used. Immunoreactivity was classified according to the scale presented in the HercepTest Scoring Guidelines. Twenty-two cases (17.1%) had a score of 0, 28 cases (21.7%) had of a score of 1+, 41 cases (31.8%) had a score of 2+, and 38 cases (29.4%) had a score of 3+. Therefore, HER2 overexpression (score 2+ or 3+) was observed in 79 cases (61.2%). Patients with HER2 overexpression tumors had significantly shorter survival times than those with HER2 normal expression (score 0 or 1+) tumors (median survival time, 14.7 vs 20.7 months, respectively; P = 0.0078 on the log-rank test). On multivariate survival analysis, HER2 overexpression remained an independent prognostic factor (hazard ratio, 1.806; P = 0.0258). A significant percentage of pancreatic cancers were demonstrated to have HER2 overexpression, and overexpression of this tyrosine kinase receptor proved to be an independent factor for a worse prognosis. These results should encourage further investigation of treatments using new molecular targeting agents against HER2 protein to improve the survival of pancreatic cancer patients. (Cancer Sci 2009; 100: 1243-1247)